Terms: = Brain cancer AND AKT2, PKBBETA, 208, ENSG00000105221, RAC-BETA, P31751, PRKBB AND Clinical Outcome
3 results:
1. Blocking LINC00152 suppresses glioblastoma malignancy by impairing mesenchymal phenotype through the miR-612/akt2/NF-κB pathway.
Cai J; Zhang J; Wu P; Yang W; Ye Q; Chen Q; Jiang C
J Neurooncol; 2018 Nov; 140(2):225-236. PubMed ID: 30043319
[TBL] [Abstract] [Full Text] [Related]
2. Radiomic MRI signature reveals three distinct subtypes of glioblastoma with different clinical and molecular characteristics, offering prognostic value beyond IDH1.
Rathore S; Akbari H; Rozycki M; Abdullah KG; Nasrallah MP; Binder ZA; Davuluri RV; Lustig RA; Dahmane N; Bilello M; O'Rourke DM; Davatzikos C
Sci Rep; 2018 Mar; 8(1):5087. PubMed ID: 29572492
[TBL] [Abstract] [Full Text] [Related]
3. Tumor necrosis factor-like weak inducer of apoptosis stimulation of glioma cell survival is dependent on akt2 function.
Fortin SP; Ennis MJ; Savitch BA; Carpentieri D; McDonough WS; Winkles JA; Loftus JC; Kingsley C; Hostetter G; Tran NL
Mol Cancer Res; 2009 Nov; 7(11):1871-81. PubMed ID: 19861406
[TBL] [Abstract] [Full Text] [Related]
